🇺🇸 Valsartan Capsules in United States

14 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 14

Most-reported reactions

1. Anaemia — 2 reports (14.29%)
2. Diarrhoea — 2 reports (14.29%)
3. Gastrointestinal Haemorrhage — 2 reports (14.29%)
4. Muscular Weakness — 2 reports (14.29%)
5. Acute Kidney Injury — 1 report (7.14%)
6. Agranulocytosis — 1 report (7.14%)
7. Angioedema — 1 report (7.14%)
8. Asthenia — 1 report (7.14%)
9. Azotaemia — 1 report (7.14%)
10. Blood Creatinine Increased — 1 report (7.14%)

Source database →

Frequently asked questions

Is Valsartan Capsules approved in United States?

Valsartan Capsules does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Valsartan Capsules in United States?

Affiliated Hospital of Nantong University is the originator. The local marketing authorisation holder may differ — check the official source linked above.